Phase 2 Trial Begins of Combo Treatment for Certain B-Cell Lymphomas
News
TG Therapeutics is starting a Phase 2 clinical trial evaluating the safety and efficacy of its oral PI3K delta inhibitor, TGR-1202, in combination with Imbruvica (ibrutinib) to treat relapsed or refractory ... Read more